RESUMEN
The present study aimed to assess the effectiveness and functional adverse effects of a single and multiple injections of botulinum toxin A (BoNT-A) for masseter hypertrophy (MH). Twenty-six women complaining about lower third facial enlargement due to MH, received 75 U of BoNT-A (abobotulinum toxin) in each masseter muscles. After 3 months, patients were randomly assigned to receive a second treatment session of Saline Solution: (G1; n = 11) or BoNT-A: (G2; n = 12). Muscle thickness (ultrasound), electrical activity (electromyography; EMG), masticatory performance, and subjective perception of MH were evaluated. Follow-up was performed at 1, 3 and 6 months. Muscle thickness, EMG activity, and masticatory performance were analyzed using ANOVA two-way and Sidak test as post-hoc. Masticatory performance was analyzed by the Friedman's test and Mann-Whitney test. Regarding inter-groups comparisons, there was a significant decrease in the left masseter muscle thickness in the G2 group at the 6 month follow-up (p < 0.02). For EMG, significant differences were evident at the 6 month assessment, with higher masseter activity for G1 (p < 0.05). For masticatory performance, no significant differences were observed throughout the study (p > 0.05) and a higher improvement in subjective perception of MH was observed in the 1 month follow-up for G2 (p < 0.05). In conclusion, BoNT-A is effective for MH, however multiple injections cause functional adverse effects in masseter muscle.
Asunto(s)
Toxinas Botulínicas Tipo A , Electromiografía , Hipertrofia , Músculo Masetero , Humanos , Músculo Masetero/efectos de los fármacos , Músculo Masetero/patología , Músculo Masetero/anomalías , Femenino , Hipertrofia/tratamiento farmacológico , Toxinas Botulínicas Tipo A/administración & dosificación , Toxinas Botulínicas Tipo A/uso terapéutico , Toxinas Botulínicas Tipo A/efectos adversos , Adulto , Masticación/efectos de los fármacos , Persona de Mediana Edad , Resultado del Tratamiento , Fármacos Neuromusculares/uso terapéutico , Fármacos Neuromusculares/administración & dosificación , Inyecciones IntramuscularesRESUMEN
BACKGROUND: Eventually Oral submucous fibrosis causes pronounced stiffness and failure to open the mouth. Objectives are to determine compare the efficacy of intralesional steroids alone and combination of steroids with hyaluronidase on mouth opening in oral submucous fibrosis. METHODS: It was a prospective comparative cohort study. Total of 74 patients both male and female having history of pan chewing and limited mouth opening and burning sensations were included in the study. Informed consent was taken and divided into two groups. Patients of group 1 were managed with mixture of betamethasone 1 ml and hyaluronidase 1500 IU and patients of group 2 were treated with only steroid injection of betamethasone 1 ml given intralesional, both injections were given intralesional, by multiple puncture technique and once a week and continued for twelve weeks (3 months). And data compiled and analyzed in SPSS-20. RESULTS: The mean age of group 1 was 40.027±6.97 years, and mean age of Group 2 was 37.351±5.48 years. In both groups, the greatest number of cases aged from 31-59 years. Compared to females in both groups, the majority of patients were males. In 32 (86.4)% patients of group 1 showed efficacy compared with 18[43.2] patients in group 2 [p-0.000]. Conclusion: In this study Intralesional steroids with hyaluronidase injections are more efficient for opening the mouth in patients with oral sub-mucus fibrosis.
Asunto(s)
Betametasona , Glucocorticoides , Hialuronoglucosaminidasa , Boca , Fibrosis de la Submucosa Bucal , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Betametasona/farmacología , Betametasona/uso terapéutico , Estudios de Cohortes , Hialuronoglucosaminidasa/farmacología , Hialuronoglucosaminidasa/uso terapéutico , Fibrosis de la Submucosa Bucal/tratamiento farmacológico , Fibrosis de la Submucosa Bucal/fisiopatología , Estudios Prospectivos , Glucocorticoides/farmacología , Glucocorticoides/uso terapéutico , Masticación/efectos de los fármacos , Boca/efectos de los fármacos , Boca/fisiopatologíaRESUMEN
To cover the unpleasant taste of amoxicillin (250 mg), maize starch (baby food) and milk chocolate were co-formulated. The raw materials and the final formulations were characterized by means of Dynamic Light Scattering (DLS), Differential Scanning Calorimetry (DSC) and Fourier-Transform Infrared (FT-IR) spectroscopy. To evaluate the taste masking two different groups of volunteers were used, according to the Ethical Research Committee of the Aristotle University of Thessaloniki. The optimization of excipients' content in the tablet was determined by experimental design methodology (crossed D-optimal). Due to the matrix complexity, amoxicillin was extracted using liquid extraction and analyzed isocratically by HPLC. The developed chromatographic method was validated (%Recovery 98.7-101.3, %RSD = 1.3, LOD and LOQ 0.15 and 0.45 µg mL-1 respectively) according to the International Conference on Harmonization (ICH) guidelines. The physicochemical properties of the tablets were also examined demonstrating satisfactory quality characteristics (diameter: 15 mm, thickness: 6 mm, hardness <98 Newton, loss of mass <1.0%, disintegration time â¼25min). Additionally, dissolution (%Recovery >90) and in vitro digestion tests (%Recovery >95) were carried out. Stability experiments indicated that amoxicillin is stable in the prepared formulations for at least one year (%Recovery <91).
Asunto(s)
Amoxicilina/síntesis química , Antibacterianos/síntesis química , Química Farmacéutica/métodos , Composición de Medicamentos/métodos , Desarrollo de Medicamentos/métodos , Gusto/efectos de los fármacos , Administración Oral , Adolescente , Adulto , Amoxicilina/administración & dosificación , Amoxicilina/farmacocinética , Antibacterianos/administración & dosificación , Antibacterianos/farmacocinética , Aspartame/administración & dosificación , Aspartame/síntesis química , Aspartame/farmacocinética , Niño , Chocolate , Evaluación Preclínica de Medicamentos/métodos , Excipientes/administración & dosificación , Excipientes/síntesis química , Excipientes/farmacocinética , Femenino , Humanos , Masculino , Masticación/efectos de los fármacos , Masticación/fisiología , Comprimidos , Gusto/fisiología , Adulto Joven , Zea maysRESUMEN
Tardive dyskinesia (TD) is a side effect associated with the long-term use of certain antipsychotics. Considering the modulatory role of the endocannabinoid system upon dopaminergic neurotransmission, the present study tested the hypothesis that increasing endocannabinoid (anandamide and 2-arachidonoylglycerol) levels attenuates haloperidol-induced TD (vacuous chewing movements, VCMs) in male Wistar rats. The animals received administration of chronic haloperidol (38 mg/kg; 29 days) followed by acute FAAH (URB597, 0.1-0.5 mg/kg) or MAGL (JZL184, 1-10 mg/kg) inhibitors before VCM quantification. The underlying mechanisms were evaluated by pre-treatments with a CB1 receptor antagonist (AM251, 1 mg/kg) or a TRPV1 channel blocker (SB366791, 1 mg/kg). Moreover, CB1 receptor expression was evaluated in the striatum of high-VCM animals. As expected, haloperidol induced VCMs only in a subset of rats. Either FAAH or MAGL inhibition reduced VCMs. These effects were prevented by CB1 receptor antagonism, but not by TRPV1 blockage. Remarkably, CB1 receptor expression was increased high-VCM rats, with a positive correlation between the levels of CB1 expression and the number of VCMs. In conclusion, increasing endocannabinoid levels results in CB1 receptor-mediated protection against haloperidol-induced TD in rats. The increased CB1 receptor expression after chronic haloperidol treatment suggests a counter-regulatory protective mechanism.
Asunto(s)
Agonistas de Receptores de Cannabinoides/farmacología , Discinesia Inducida por Medicamentos/tratamiento farmacológico , Endocannabinoides/metabolismo , Haloperidol/efectos adversos , Animales , Antipsicóticos/efectos adversos , Ácidos Araquidónicos/farmacología , Antagonistas de Receptores de Cannabinoides/farmacología , Cuerpo Estriado/efectos de los fármacos , Modelos Animales de Enfermedad , Discinesia Inducida por Medicamentos/metabolismo , Endocannabinoides/farmacología , Glicéridos/farmacología , Masculino , Masticación/efectos de los fármacos , Alcamidas Poliinsaturadas/farmacología , Ratas , Ratas Wistar , Receptor Cannabinoide CB1/metabolismo , Canales Catiónicos TRPV/metabolismo , Discinesia Tardía/tratamiento farmacológico , Discinesia Tardía/metabolismoRESUMEN
Tardive dyskinesia (TD) is a movement disorder that appears after chronic use of drugs that block dopaminergic receptors such as antipsychotics. Besides the motor symptoms, patients with TD also present cognitive deficits. Neuroinflammatory mechanisms could be involved in the development of these symptoms. A previous study showed that cannabidiol (CBD), the major non-psychotomimetic compound of Cannabis sativa plant, prevents orofacial dyskinesia induced by typical antipsychotics by activating peroxisome proliferator-activated receptors gamma (PPARγ). Here, we investigated if CBD would also reverse haloperidol-induced orofacial dyskinesia and associated cognitive deficits. We also verified if these effects depend on PPARγ receptor activation. Daily treatment with haloperidol (3 mg/kg, 21 days) increased the frequency of vacuous chewing movements (VCM) and decreased the discrimination index in the novel object recognition test in male Swiss mice. CBD (60 mg/kg/daily) administered in the last 7 days of haloperidol treatment attenuated both behavioral effects. Furthermore, haloperidol increased IL-1ß and TNF-α levels in the striatum and hippocampus while CBD reverted these effects. The striatal and hippocampal levels of proinflammatory cytokines correlated with VCM frequency and discrimination index, respectively. Pretreatment with the PPARγ antagonist GW9662 (2 mg/kg/daily) blocked the behavioral effects of CBD. In conclusion, these results indicated that CBD could attenuate haloperidol-induced orofacial dyskinesia and improve non-motor symptoms associated with TD by activating PPARγ receptors.
Asunto(s)
Antipsicóticos/efectos adversos , Cannabidiol/farmacología , Disfunción Cognitiva , Discinesias/tratamiento farmacológico , PPAR gamma/uso terapéutico , Discinesia Tardía/inducido químicamente , Animales , Antidiscinéticos/efectos adversos , Antidiscinéticos/farmacología , Conducta Animal/efectos de los fármacos , Cannabidiol/administración & dosificación , Disfunción Cognitiva/tratamiento farmacológico , Disfunción Cognitiva/prevención & control , Cuerpo Estriado/efectos de los fármacos , Haloperidol/efectos adversos , Haloperidol/farmacología , Masculino , Masticación/efectos de los fármacos , Ratones , Neostriado/efectos de los fármacos , Ratas , Ratas WistarRESUMEN
Huntington's disease (HD) is a progressive, neurodegenerative and inherited disease and recent years have witnessed the understanding of the cellular and molecular mechanisms related to HD. Safranal, an organic compound isolated from saffron, has been reported to have anti-apoptotic, anti-inflammatory and antioxidant activity and has studied in chronic and neurodegenerative disease. Therefore, this study was aimed to investigate the effect of safranal on 3-NP induced locomotor activity and biochemical alterations in rats. To this aim, 40 male Wistar rats weighting 250-300 g were divided into 5 groups (n = 8) including sham, 3-NP group (10 mg/kg) as control and treatment groups (3-NP + safranal 0.75, 1.5 and 3 mg/kg) in two weeks duration of treatment. Behavioral/movement assessments in addition to oxidant/antioxidant markers in rat cortex and striatum were evaluated in control and treatment groups. Here, we found that safranal significantly alleviated 3-NP-induced changes of body weight, rotarod activity, number of vacuous chewing movements (VCMs), and locomotor activity. In addition, brain tissue assessments in cortex and striatum revealed that safranal could prevent the elevation of nitrite and malondialdehyde (MDA) levels as well as decrease of superoxide dismutase (SOD), catalase activity and glutathione (GSH) induced by 3-NP. In conclusion our results showed that safranal prevented the motor dysfunction induced by 3-NP in animal model of Huntington's disease. This effect might be due to its modulating effect on oxidants-antioxidant balance.
Asunto(s)
Antioxidantes/uso terapéutico , Ciclohexenos/uso terapéutico , Enfermedad de Huntington/tratamiento farmacológico , Fármacos Neuroprotectores/uso terapéutico , Terpenos/uso terapéutico , Animales , Conducta Animal/efectos de los fármacos , Peso Corporal/efectos de los fármacos , Catalasa/metabolismo , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/enzimología , Glutatión/metabolismo , Enfermedad de Huntington/inducido químicamente , Enfermedad de Huntington/enzimología , Locomoción/efectos de los fármacos , Masculino , Malondialdehído/metabolismo , Masticación/efectos de los fármacos , Nitrocompuestos , Propionatos , Ratas Wistar , Prueba de Desempeño de Rotación con Aceleración Constante , Superóxido Dismutasa/metabolismoRESUMEN
Purpose Children with cerebral palsy (CP) often exhibit difficulties in feeding resulting from deficits in chewing. This study investigates the therapeutic potential of L-tryptophan (TRI) to reduce deficits in chewing in rats subjected to an experimental model of CP.Methods A total of 80 Wistar albino rats were used. Pups were randomly assigned to 4 experimental groups: Control Saline, Control TRI, CP Saline, and CP TRI groups. The experimental model of CP was based on the combination of perinatal anoxia associated with postnatal sensorimotor restriction of the hind limbs. TRI was administered subcutaneously during the lactation period. Anatomical and behavioral parameters were evaluated during maturation, including body weight gain, food intake, chewing movements, relative weight and the distribution of the types of masseter muscle fibers.Results The induction of CP limited body weight gain, decreased food intake and led to impairment in the morphological and functional parameters of chewing. Moreover, for a comparable amount of food ingested, CP TRI animals grew the most. In addition, supplementation with TRI improved the number of chewing movements, and increased the weight and proportion of type IIB fibers of the masseter in rats subjected to CP.Conclusion These results demonstrate that experimental CP impaired the development of mastication and that TRI supplementation increased masticatory maturation in animals subjected to CP.
Asunto(s)
Parálisis Cerebral/fisiopatología , Masticación/efectos de los fármacos , Masticación/fisiología , Triptófano/uso terapéutico , Animales , Parálisis Cerebral/tratamiento farmacológico , Modelos Animales de Enfermedad , Ingestión de Alimentos , Músculo Masetero/efectos de los fármacos , Músculo Masetero/fisiopatología , Fenotipo , Ratas , Ratas Wistar , Aumento de Peso/efectos de los fármacosRESUMEN
OBJECTIVES: This prospective observational study aimed to evaluate discomfort after extraction of deciduous teeth under local anesthesia. The primary objective was to describe the prevalence of post-extraction pain (PEP), post-extraction bleeding (PEB), post-extraction biting injury (PEBI), and analgesic usage in children. The secondary objective was to define whether it is possible to determine a profile of patients or a type of extraction procedure predictive to PEP, administration of analgesics, PEB, or PEBI. METHODS: One hundred and twenty-five children, aged 3-13 years, with indications of at least one deciduous tooth extraction, were included. Immediately after extraction, information concerning the patient and the extraction were collected. Eighteen to 32 hr after extraction, parents were called by phone to request reports concerning the onset and intensity of PEP assessed using the Wong-Baker Faces (WBF) scale, the administration of paracetamol (acetaminophen) to their children, and the appearance of PEB and/or PEBI. RESULTS: Of the children, 37.3% reported PEP (WBF ≥2), but 23.3% of these children did not receive any analgesic drugs to help relieve pain. Pain appeared before 3 hr after extraction in 69% of the children. Higher incidences of PEP and usage of analgesics were found both in the group of children with unfavorable socioeconomic level compared to favorable level and in the group with pre-operative pain compared to no pre-operative pain (p < .05). CONCLUSIONS: About a third of the children reported pain after extraction, but the instructions for pain relief were not followed by all parents. The socioeconomic level of the young patient and the pain felt during the extraction were important predictors of discomfort. Therefore, our study could help the dentist to provide information on predicted post-operative discomfort and to allow suitable care depending on the patient's profile or procedure.
Asunto(s)
Mucosa Bucal/lesiones , Dolor Postoperatorio/epidemiología , Hemorragia Posoperatoria/epidemiología , Extracción Dental/efectos adversos , Diente Primario/cirugía , Acetaminofén/administración & dosificación , Adolescente , Analgésicos/administración & dosificación , Analgésicos no Narcóticos/administración & dosificación , Anestésicos Locales/administración & dosificación , Anestésicos Locales/efectos adversos , Niño , Preescolar , Femenino , Humanos , Incidencia , Lidocaína/administración & dosificación , Lidocaína/efectos adversos , Masculino , Masticación/efectos de los fármacos , Manejo del Dolor/estadística & datos numéricos , Dimensión del Dolor/estadística & datos numéricos , Dolor Postoperatorio/tratamiento farmacológico , Dolor Postoperatorio/etiología , Dolor Postoperatorio/prevención & control , Hemorragia Posoperatoria/etiología , Hemorragia Posoperatoria/prevención & control , Prevalencia , Estudios Prospectivos , Extracción Dental/métodos , Extracción Dental/estadística & datos numéricosRESUMEN
This study evaluated the effect of (+)-catechin, a polyphenolic compound, on orofacial dyskinesia (OD) induced by reserpine in mice. The potential modulation of monoaminoxidase (MAO) activity, tyrosine hydroxylase (TH) and glutamic acid decarboxylase (GAD67) immunoreactivity by catechin were used as biochemical endpoints. The interaction of catechin with MAO-A and MAO-B was determined in vitro and in silico. The effects of catechin on OD induced by reserpine (1 mg/kg for 4 days, subcutaneously) in male Swiss mice were examined. After, catechin (10, 50 or 100 mg/kg, intraperitoneally) or its vehicle were given for another 20 days. On the 6th, 8th, 15th and 26th day, vacuous chewing movements (VCMs) and locomotor activity were quantified. Biochemical markers (MAO activity, TH and GAD67 immunoreactivity) were evaluated in brain structures. In vitro, catechin inhibited both MAO isoforms at concentrations of 0.34 and 1.03 mM being completely reversible for MAO-A and partially reversible for MAO-B. Molecular docking indicated that the catechin bound in the active site of MAO-A, while in the MAO-B it interacted with the surface of the enzyme in an allosteric site. In vivo, reserpine increased the VCMs and decreased the locomotor activity. Catechin (10 mg/kg), decreased the number of VCMs in the 8th day in mice pre-treated with reserpine without altering other behavioral response. Ex vivo, the MAO activity and TH and GAD67 immunoreactivity were not altered by the treatments. Catechin demonstrated a modest and transitory protective effect in a model of OD in mice.
Asunto(s)
Catequina/uso terapéutico , Discinesias/tratamiento farmacológico , Discinesias/metabolismo , Masticación/efectos de los fármacos , Actividad Motora/efectos de los fármacos , Reserpina/toxicidad , Animales , Antipsicóticos/toxicidad , Catequina/farmacología , Relación Dosis-Respuesta a Droga , Masculino , Masticación/fisiología , Ratones , Simulación del Acoplamiento Molecular/métodos , Inhibidores de la Monoaminooxidasa/farmacología , Inhibidores de la Monoaminooxidasa/uso terapéutico , Actividad Motora/fisiología , Estructura Secundaria de Proteína , Resultado del TratamientoRESUMEN
This study assessed the safety and efficacy of three different doses of BoNT-A for persistent myofascial pain (MFP). One hundred female subjects were randomly assigned into five groups (n = 20): oral appliance (OA), saline solution (SS) and three BoNT-A groups with different doses. Pain intensity and pressure pain threshold were evaluated up to 24 weeks after treatment. Adverse effects related to muscle contraction, masticatory performance, muscle thickness and mandibular bone volume were also assessed. Changes over time were compared within and between groups. The "nparLD" package and Wilcoxon signed-rank test were used to analyze the data. BoNT-A reduced pain intensity (p < 0.0001) and increased pressure pain threshold (p < 0.0001) for up to 24 weeks compared to the placebo. No differences were found between BoNT-A and OA at the last follow-up. A transient decline in masticatory performance (p < 0.05) and muscle contraction (p < 0.0001), and a decrease in muscle thickness (p < 0.05) and coronoid and condylar process bone volume (p < 0.05) were found as dose-related adverse effects of BoNT-A. Regardless of the dose, BoNT-A was as effective as OA on MFP. Notwithstanding, due to BoNT-A dose-related adverse effects, we suggest the use of low doses of BoNT-A in MFP patients that do not benefit from conservative treatments.
Asunto(s)
Analgésicos/administración & dosificación , Toxinas Botulínicas Tipo A/administración & dosificación , Dolor Facial/tratamiento farmacológico , Umbral del Dolor/efectos de los fármacos , Adulto , Analgésicos/efectos adversos , Toxinas Botulínicas Tipo A/efectos adversos , Brasil , Relación Dosis-Respuesta a Droga , Dolor Facial/diagnóstico , Dolor Facial/fisiopatología , Femenino , Humanos , Masticación/efectos de los fármacos , Dimensión del Dolor , Factores de Tiempo , Resultado del TratamientoRESUMEN
Objectives: Tardive dyskinesia (TD) unlike acute dystonia may be irreversible. This study investigated the effects of oral cannabidiol (CBD) on haloperidol-induced vacuous chewing movement (VCM) model of TD. Methods: There were six experimental groups with different combinations of oral cannabidiol with 5 mg/kg of haloperidol given orally. Behavioural assays and FBS were measured. VCMs were assessed after the last dose of medication. Blood for oxidative stress assays was collected on the 8th day after the administration of the last dose of medication. Results: This study found that CBD co-administration with haloperidol attenuated the VCMs and increased motor tone produced by haloperidol. CBD alone at 5 mg/kg appears to have anxiolytic properties but may not be as effective as haloperidol which exhibited a greater anxiolytic effect at 5 mg/kg. Treatment with CBD alone at 5 mg/kg also appeared to enhance brain DPPH scavenging activity. Conclusions: We confirmed that CBD can ameliorate motor impairments produced by haloperidol. Our data suggest that CBD can be combined with haloperidol to prevent the emergent of extrapyramidal side effects and long-term movement disorders, such as acute dystonic disorder and TD.
Asunto(s)
Glucemia/efectos de los fármacos , Cannabidiol/farmacología , Discinesia Inducida por Medicamentos , Haloperidol/administración & dosificación , Haloperidol/efectos adversos , Locomoción/efectos de los fármacos , Masticación/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Administración Oral , Animales , Antipsicóticos/administración & dosificación , Antipsicóticos/efectos adversos , Cannabidiol/administración & dosificación , Discinesia Inducida por Medicamentos/sangre , Discinesia Inducida por Medicamentos/tratamiento farmacológico , Discinesia Inducida por Medicamentos/metabolismo , Discinesia Inducida por Medicamentos/prevención & control , Masculino , Ratas , Ratas WistarRESUMEN
Haloperidol is a first-generation antipsychotic used in the treatment of psychoses, especially schizophrenia. This drug acts by blocking dopamine D2 receptors, reducing psychotic symptoms. Notwithstanding its benefits, haloperidol also produces undesirable impacts, in particular extrapyramidal effects such as tardive dyskinesia (TD), which limit the use of this and related drugs. TD is characterized by repetitive involuntary movements occurring after chronic exposure therapy with haloperidol. Symptoms most commonly manifest in the orofacial area and include involuntary movements, tongue protrusion, pouting lips, chewing in the absence of any object to chew, and facial grimacing. The most serious aspect of TD is that it may persist for months or years after drug withdrawal and is irreversible in some patients. This unit, aimed at facilitating the study of TD, describes methods to induce TD in rats using haloperidol, as well as procedures for evaluating the animals's TD-related symptoms. © 2019 by John Wiley & Sons, Inc.
Asunto(s)
Antipsicóticos/toxicidad , Modelos Animales de Enfermedad , Haloperidol/toxicidad , Masticación/efectos de los fármacos , Discinesia Tardía/inducido químicamente , Animales , Evaluación Preclínica de Medicamentos/métodos , Masculino , Masticación/fisiología , Ratas , Ratas Wistar , Discinesia Tardía/fisiopatologíaRESUMEN
BACKGROUND: The Test of Masticating and Swallowing Solids (TOMASS) has been developed to provide clinicians with objective data regarding the efficiency of oral phase function and solid bolus ingestion. AIMS: To determine if the TOMASS will detect changes in the oral phase of swallowing imposed by topical anaesthesia, thus providing validation of its clinical utility. METHODS & PROCEDURES: Per the standard protocol, 10 healthy participants ate one-quarter of an Arnotts SaladaTM biscuit. The number of bites per cracker, number of masticatory cycles, number of swallows and total time taken were recorded at baseline, following application of topical oral anaesthetic; this was additionally compared with a post-anaesthetic condition. Median and interquartile range (IQR) were calculated. Wilcoxon signed-rank tests were conducted to evaluate trial effect, and Friedman's tests were used to detect differences in the number of bites, number of swallows, number of chews and time taken to eat the crackers. OUTCOMES & RESULTS: Results indicated that the number of both bites and swallows did not significantly change across conditions (χ²(2) = 0.105, p = 0.949, χ²(2) = 1.357, p = 0.507); however, the number of chews for the anaesthetic condition was significantly higher when compared with the baseline (p = 0.02) and post-anaesthesia conditions (p = 0.02). Further, the durations of ingestion in the anaesthetic condition were significantly longer than the baseline (p = 0.01) and post-anaesthesia (p = 0.01) conditions. Across all measures, there were no differences between baseline and post-anaesthesia conditions. CONCLUSIONS & IMPLICATIONS: Although further exploration is required, these early data suggest the TOMASS is a sensitive measure in the evaluation of the oral-phase preparation of solid textures.
Asunto(s)
Trastornos de Deglución/diagnóstico , Deglución/fisiología , Técnicas de Diagnóstico del Sistema Digestivo/normas , Masticación/fisiología , Anestésicos Locales/farmacología , Deglución/efectos de los fármacos , Trastornos de Deglución/inducido químicamente , Trastornos de Deglución/fisiopatología , Femenino , Humanos , Masculino , Masticación/efectos de los fármacos , Sensibilidad y Especificidad , Factores de Tiempo , Adulto JovenRESUMEN
Grain-rich diets often lead to subacute ruminal acidosis (SARA) impairing rumen and systemic cattle health. Recent data suggest beneficial effects of a clay mineral (CM)- based product on the rumen microbiome of cattle during SARA. This study sought to investigate whether the CM supplementation can counteract SARA-induced perturbations of the bovine systemic health. The study used an intermittent diet-induced SARA-model with eight dry Holstein cows receiving either no additive as control or CM via concentrates (n=8 per treatment). Cows received first a forage diet (Baseline) for 1 week, followed by a 1-week SARA-challenge (SARA 1), a 1-week recovery phase (Recovery) and finally a second SARA-challenge for 2 weeks (SARA 2). Cows were monitored for feed intake, reticular pH and chewing behavior. Blood samples were taken and analyzed for metabolites related to glucose and lipid metabolism as well as liver health biomarkers. In addition, a targeted electrospray ionization-liquid chromatography-MS-based metabolomics approach was carried out on the plasma samples obtained at the end of the Baseline and SARA 1 phase. Data showed that supplementing the cows' diet with CM improved ruminating chews per regurgitated bolus by 16% in SARA 1 (P=0.01) and enhanced the dry matter intake during the Recovery phase (P=0.05). Moreover, the SARA-induced decreases in several amino acids and phosphatidylcholines were less pronounced in cows receiving CM (P≤0.10). The CM-supplemented cows also had lower concentrations of lactate (P=0.03) and biogenic amines such as histamine and spermine (P<0.01) in the blood. In contrast, the concentration of acylcarnitines with key metabolic functions was increased in the blood of treated cows (P≤0.05). In SARA 2, the CM-cows had lower concentrations of the liver enzymes aspartate aminotransferase and γ-glutamyltransferase (P<0.05). In conclusion, the data suggest that supplementation of CM holds the potential to alleviate the negative effects of high-grain feeding in cattle by counteracting multiple SARA-induced perturbations in the systemic metabolism and liver health.
Asunto(s)
Bovinos/fisiología , Arcilla , Ingestión de Alimentos , Hígado/enzimología , Minerales/metabolismo , Plasma/química , Rumen/fisiología , Alimentación Animal/análisis , Animales , Bovinos/sangre , Estudios Cruzados , Dieta/veterinaria , Suplementos Dietéticos/análisis , Ingestión de Alimentos/efectos de los fármacos , Grano Comestible/fisiología , Concentración de Iones de Hidrógeno , Masticación/efectos de los fármacos , Metaboloma , Minerales/administración & dosificación , Plasma/metabolismo , Rumen/efectos de los fármacosRESUMEN
BACKGROUND AND OBJECTIVE: In clinical practice, malocclusion is often encountered during the period of growth and development of individuals. In addition to nutritional imbalance, some studies have found that mastication affects learning and memory ability. Tooth loss and masticatory hypofunction have been suggested as risk factors of Alzheimer disease. However, relatively little research has been done in developing animals. The present study evaluated the relationship between masticatory hypofunction and neuropathological changes of the hippocampus in developing rats. DESIGN: Four-week-old Wistar rats were randomly divided into saline-injected and botulinum toxin type A (BTXA)-injected groups. After an experiment period of 4 weeks, the rats were sacrificed for evaluation of neuropathological changes in the hippocampus through Nissl staining and phosphorylated cyclic AMP (cAMP) response element binding protein (CREB) immunohistochemistry. RESULTS: Nissl staining revealed a significant reduction in the density of neurons in the BTXA-injected rats. The BTXA-injected rats exhibited a decreased level of CREB phosphorylation. The degree of p-CREB immunoreactivity differed significantly between the two groups. CONCLUSION: The BTXA-injected rats exhibited a reduction in neuron density and phosphorylated CREB, indicating that mastication might influence the learning and memory ability during the growth period. Therefore, it is strongly suggested that malocclusion be corrected as soon as possible during growth and development.
Asunto(s)
Toxinas Botulínicas Tipo A , Masticación , Animales , Ratas , Toxinas Botulínicas Tipo A/farmacología , Proteína de Unión a Elemento de Respuesta al AMP Cíclico , Hipocampo/crecimiento & desarrollo , Inmunohistoquímica , Masticación/efectos de los fármacos , Neuronas/metabolismo , Distribución Aleatoria , Ratas WistarRESUMEN
The chronic use of drugs that reduce the dopaminergic neurotransmission can cause a hyperkinetic movement disorder called tardive dyskinesia (TD). The pathophysiology of this disorder is not entirely understood but could involve oxidative and neuroinflammatory mechanisms. Cannabidiol (CBD), the major non-psychotomimetic compound present in Cannabis sativa plant, could be a possible therapeutic alternative for TD. This phytocannabinoid shows antioxidant, anti-inflammatory and antipsychotic properties and decreases the acute motor effects of classical antipsychotics. The present study investigated if CBD would attenuate orofacial dyskinesia, oxidative stress and inflammatory changes induced by chronic administration of haloperidol in mice. Furthermore, we verified in vivo and in vitro (in primary microglial culture) whether these effects would be mediated by PPARγ receptors. The results showed that the male Swiss mice treated daily for 21â¯days with haloperidol develop orofacial dyskinesia. Daily CBD administration before each haloperidol injection prevented this effect. Mice treated with haloperidol showed an increase in microglial activation and inflammatory mediators in the striatum. These changes were also reduced by CBD. On the other hand, the levels of the anti-inflammatory cytokine IL-10 increased in the striatum of animals that received CBD and haloperidol. Regarding oxidative stress, haloperidol induced lipid peroxidation and reduced catalase activity. This latter effect was attenuated by CBD. The combination of CBD and haloperidol also increased PGC-1α mRNA expression, a co-activator of PPARγ receptors. Pretreatment with the PPARγ antagonist, GW9662, blocked the behavioural effect of CBD in our TD model. CBD also prevented LPS-stimulated microglial activation, an effect that was also antagonized by GW9662. In conclusion, our results suggest that CBD could prevent haloperidol-induced orofacial dyskinesia by activating PPARγ receptors and attenuating neuroinflammatory changes in the striatum.
Asunto(s)
Cannabidiol/farmacología , Masticación/efectos de los fármacos , Actividad Motora/efectos de los fármacos , PPAR gamma/metabolismo , Animales , Antioxidantes/metabolismo , Antipsicóticos/uso terapéutico , Conducta Animal/efectos de los fármacos , Encéfalo/metabolismo , Cannabidiol/metabolismo , Cuerpo Estriado/metabolismo , Discinesia Inducida por Medicamentos/metabolismo , Discinesias/tratamiento farmacológico , Discinesias/metabolismo , Femenino , Haloperidol/farmacología , Inflamación/metabolismo , Inflamación/patología , Masculino , Ratones , Ratones Endogámicos C57BL , Microglía/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Cultivo Primario de Células , Superóxido Dismutasa/metabolismo , Discinesia Tardía/inducido químicamente , Discinesia Tardía/tratamiento farmacológicoRESUMEN
The evaluation of three-dimensional occlusal loading during biting and chewing may assist in development of new dental materials, in designing effective and long-lasting restorations such as crowns and bridges, and for evaluating functional performance of prosthodontic components such as dental and/or maxillofacial implants. At present, little is known about the dynamic force and pressure distributions at the occlusal surface during mastication, as these quantities cannot be measured directly. The aim of this study was to evaluate subject-specific occlusal loading forces during mastication using accurate jaw motion measurements. Motion data was obtained from experiments in which an individual performed maximal effort dynamic chewing cycles on a rubber sample with known mechanical properties. A finite element model simulation of one recorded chewing cycle was then performed to evaluate the deformation of the rubber. This was achieved by imposing the measured jaw motions on a three-dimensional geometric surface model of the subject's dental impressions. Based on the rubber's deformation and its material behaviour, the simulation was used to compute the resulting stresses within the rubber as well as the contact pressures and forces on the occlusal surfaces. An advantage of this novel modelling approach is that dynamic occlusal pressure maps and biting forces may be predicted with high accuracy and resolution at each time step throughout the chewing cycle. Depending on the motion capture technique and the speed of simulation, the methodology may be automated in such a way that it can be performed chair-side. The present study demonstrates a novel modelling methodology for evaluating dynamic occlusal loading during biting or chewing.
Asunto(s)
Fuerza de la Mordida , Oclusión Dental , Masticación/fisiología , Adulto , Placas Óseas , Materiales Dentales/farmacología , Humanos , Masculino , Mandíbula/efectos de los fármacos , Mandíbula/fisiología , Masticación/efectos de los fármacos , Presión , Soporte de PesoRESUMEN
Tardive dyskinesia (TD) is a common adverse effect observed in patients with long-term use of typical antipsychotic medications. A vacuous chewing movement (VCM) model induced by haloperidol has been used to study these abnormalities in experimental animals. The cause of TD and its treatment remain unknown, but several lines of evidence suggest that dopamine receptor supersensitivity and gamma-aminobutyric acid (GABA) insufficiency play important roles in the development of TD. This study investigated the effects of treatment with the GABA-mimetic drug gabapentin on the development of haloperidol-induced VCMs. Male mice received vehicle, haloperidol (1.5â¯mg/kg), or gabapentin (GBP, 100â¯mg/kg) intraperitoneally during 28 consecutive days. Quantification of VCMs was performed before treatment (baseline) and on day 28, and an open-field test was also conducted on the 28th day of treatment. The administration of gabapentin prevented the manifestation of haloperidol-induced VCMs. Treatment with haloperidol alone reduced the locomotor activity in the open-field test that was prevented by co-treatment with gabapentin. We did not find any differences among the groups nor in the tyrosine hydroxylase (TH) or glutamic acid decarboxylase (GAD) immunoreactivity or monoamine levels in the striatum of mice. These results suggest that treatment with gabapentin, an analog of GABA, can attenuate the VCMs induced by acute haloperidol treatment in mice without alterations in monoamine levels, TH, or GAD67 immunoreactivity in the striatum.
Asunto(s)
Antagonistas de Dopamina/toxicidad , Moduladores del GABA/farmacología , Gabapentina/farmacología , Haloperidol/toxicidad , Masticación/efectos de los fármacos , Animales , Ansiolíticos/farmacología , Antidiscinéticos/toxicidad , Masculino , Masticación/fisiología , RatonesRESUMEN
Parkinson's disease (PD) is a neurodegenerative disease characterized by a progressive degeneration of dopaminergic neurons in the substantia nigra pars compact (SNpc), with consequent depletion of dopamine in the striatum, which gives rise to the characteristic motor symptoms of PD. Although its etiology is unknown, several studies have suggested that oxidative stress plays a critical function in the pathophysiology of PD, and antioxidant agents could be helpful to slown down the dopaminergic neurodegeneration. Carvacrol (CA) is a phenolic monoterpene found in essential oils of many aromatic plants that presents antioxidant and neuroprotective effects. This study aimed to assess the effect of CA in a reserpine (RES)-induced rat model of PD. Male Wistar rats received 15â¯s.c. injections of 0.1â¯mg/kg RES or vehicle, every other day, concomitantly to daily i.p. injections of CA (12.5 or 25â¯mg/kg) or vehicle. Across the treatment, the animals were submitted to behavioral evaluation in the catalepsy test (performed daily), open field test (7th day) and assessment of vacuous chewing movements (12th, 20th and 30th days). Upon completion of behavioral tests, rats were perfused and their brains underwent tyrosine hydroxylase (TH) immunohistochemical analysis. Our results showed that CA (12.5 e 25â¯mg/kg) prevented the increase in catalepsy behavior and number of vacuous chewing movements, but failed to revert the decreased open-field locomotor activity induced by RES. In addition, CA in both doses prevented the decrease in TH immunostaining induced by RES in the SNpc and dorsal striatum. Taken together, our results suggest that CA shows a protective effect in a rat model of PD, preventing motor and neurochemical impairments induced by RES. Thus, the use of CA as a promising new strategy for the prevention and/or treatment of PD may be considered.
Asunto(s)
Antiparasitarios/uso terapéutico , Antipsicóticos/toxicidad , Monoterpenos/uso terapéutico , Trastornos Parkinsonianos/inducido químicamente , Reserpina/toxicidad , Tirosina 3-Monooxigenasa/metabolismo , Análisis de Varianza , Animales , Catalepsia/diagnóstico , Catalepsia/etiología , Cimenos , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Conducta Exploratoria/efectos de los fármacos , Locomoción/efectos de los fármacos , Masculino , Masticación/efectos de los fármacos , Trastornos Parkinsonianos/fisiopatología , Ratas , Ratas Wistar , Proteínas de Transporte Vesicular de Monoaminas/metabolismoRESUMEN
Feeding of concentrate-rich diets impairs chewing behavior and leads to rumen acidosis in cattle. Because of their modulatory effects on ruminal fermentation, phytogenic compounds (PHY) and autolyzed yeast derivatives (AY) may alleviate the negative consequences of high-concentrate diets. Therefore, this research investigated if chewing behavior and the reticular pH dynamics are modulated by AY and PHY supplementation during repeated concentrate-rich challenges used to simulate intermittent rumen acidotic insults. Eight rumen-cannulated, dry, and nonpregnant Holstein cows were assigned to an incomplete double 4 × 3 Latin square design with 3 treatments and 4 experimental runs (n = 8/treatment). Cows were fed concentrates either not supplemented (CON) or supplemented with PHY or AY. Initially, cows were fed a pure forage diet (FD) and switched to a 65% concentrate diet on DM basis for 1 (CONC 1) and 2 (CONC 2) wk. Between CONC 1 and CONC 2, the cows were fed the FD for 1 wk. Chewing activity was measured using noseband sensors and reticular pH by wireless pH sensors. Data showed that cows spent less time ruminating in CONC 1 than in CONC 2. In agreement, reticular pH drop was more pronounced during CONC 1 than during CONC 2. Cows fed with PHY spent 4 h less with reticular pH <6.0 during CONC 1 and 3 h less with pH <6.0 h in CONC 2 as compared with CON cows. Similarly, PHY supplementation extended rumination time with 88 min/d compared with CON cows during CONC 1. The AY supplementation increased DMI by 20% resulting in a longer eating time compared with CON diet during CONC 1. Enhancement of ruminating by PHY and eating time by AY supplementation resulted in longer total chewing time for PHY (474 min/d) and AY (466 min/d) as compared with CON (356 min/d) in CONC 1. In conclusion, cows experiencing 2 intermittent concentrate-rich challenges increased their ruminating behavior during the second challenge, and this effect was associated with higher reticular pH readings. The PHY supplementation enhanced rumination as well as reticular pH during CONC 1. However, the enhanced pH of cows fed with PHY during CONC 2 was not related to greater rumination, suggesting that influencing factors beyond rumination seemed to play a role in modulating reticular pH in PHY cows during CONC 2. The AY supplementation increased DMI without depressing rumination or reticular pH. Effects of both feed additives were more pronounced during CONC 1 challenge when reticular pH was lower.